What do the sources say about an ipamorelin and sermorelin stack?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Ipamorelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
No label, approval or human trial found gives a dose for sermorelin and ipamorelin together; the sermorelin label text reproduced by RxList gives 0.2 to 0.3 mg once daily at bedtime by subcutaneous injection, and prints the same figure as mcg in another place.1
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 5 mg | 5 mg/mL: 200 mcg is 4 units, 250 mcg is 5 units, 300 mcg is 6 units, 500 mcg is 10 units | 2.5 mg/mL: 200 mcg is 8 units, 250 mcg is 10 units, 300 mcg is 12 units, 500 mcg is 20 units | 1.667 mg/mL: 200 mcg is 12 units, 250 mcg is 15 units, 300 mcg is 18 units, 500 mcg is 30 units |
| 10 mg | 10 mg/mL: 200 mcg is 2 units, 250 mcg is 2.5 units, 300 mcg is 3 units, 500 mcg is 5 units | 5 mg/mL: 200 mcg is 4 units, 250 mcg is 5 units, 300 mcg is 6 units, 500 mcg is 10 units | 3.333 mg/mL: 200 mcg is 6 units, 250 mcg is 7.5 units, 300 mcg is 9 units, 500 mcg is 15 units |
Vial strengths and syringe marks
FDA's briefing records a compounding pharmacy website offering ipamorelin/sermorelin acetate vials of 15/18 mg and 15/9 mg.2 The sermorelin label text reproduced by RxList lists a 0.5 mg and a 3.0 mg vial, each packed with a 2 mL vial of sodium chloride injection,1 while FDA's notice names Geref vials of 0.5 mg and 1.0 mg and a 0.05 mg ampoule.3
Of the people who logged ipamorelin on its own, 79% set up a 10 mg vial and 15% a 5 mg vial.10 Of the same people, 44% set up 10 mg mixed with 2 mL.10 Of the same people, 12% set up 300 mcg at 6 units.10 The syringe mark and calculator below are for that ipamorelin-only vial, not a blend: no label or human trial found gives a dose for the blend, and the syringe arithmetic is Milligram's own.
The calculator is at the top of the page
Dose and schedule in labels and trials
The label text on RxList gives sermorelin acetate as 0.2 to 0.3 mg once daily at bedtime by subcutaneous injection.1 The same page gives sermorelin's uses as diagnostic evaluation of pituitary function and increasing growth in children.1 The same page prints the figure as mcg in another place, and the sources leave that unresolved.1
Searches of PubMed and the trials registry found no human trial of sermorelin and ipamorelin given together, and each trial below gave one of the two. The sermorelin trials were in children with growth hormone deficiency and the ipamorelin trials were in patients after bowel resection.4567
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Thorner, Geref International Study Group, 1996 (sermorelin) | 30 micrograms/kg at bedtime, subcutaneous4 | 110 previously untreated prepubertal children with GH deficiency | Up to 1 year, open label |
| Ogilvy-Stuart, 1997 (sermorelin) | 15 micrograms/kg twice daily, subcutaneous5 | Nine children with radiation-induced GH deficiency | 1 year |
| Beck, 2014, NCT00672074 (ipamorelin) | 0.03 mg/kg twice daily, intravenous, against placebo6 | 117 patients8 | Postoperative day 1 to 7 or discharge |
| NCT01280344 (ipamorelin) | 0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily, intravenous, against placebo7 | 320 patients | Outcome window up to 10 days |
FDA's briefing concludes that the evidence of effectiveness for growth hormone deficiency or postoperative ileus is limited for any route, and that there are no data supporting ipamorelin's effectiveness by the proposed subcutaneous route for these conditions.2
Of the people who logged ipamorelin, 99% logged it under the skin.10 The doses they logged were 300 mcg (22%), 200 mcg (20%), 250 mcg (16%) and 500 mcg (13%).10
Mixing and storage
The sermorelin label text says to reconstitute with sodium chloride injection, giving a solution of pH 5.0 to 5.5.1 It says to inject the diluent against the glass wall of the vial and swirl gently.1 The Irish information for Geref 50, a 50 microgram ampoule for testing pituitary function, says to reconstitute immediately before use with a minimum of 0.5 mL of the accompanying solvent and to discard any product remaining after use.9 Neither a label nor a trial found gives a water volume for a compounded vial, or says whether the two peptides can share a vial or syringe.
Unreconstituted sermorelin vials are stored refrigerated at 2° to 8°C in the US label text.1 The Irish Geref information gives a 2-year shelf life at 2°C to 8°C, protected from light.9 For ipamorelin acetate, FDA reports that the nominator's certificate of analysis gives long-term storage in a sealed container at 2°C to 8°C, and that the acetate is reported stable up to 4 years at -20°C.2 FDA also reports literature values for ipamorelin free base after reconstitution of 2 to 3 weeks at 4°C and 3 to 4 months at -20°C.2 Storage for a mixed blend is not given by any label or trial found.
Frequently asked questions
Is there an approved product that combines sermorelin and ipamorelin?
No label, approval or registered trial combining them turned up in searches of DailyMed, ClinicalTrials.gov, PubMed and FDA's pages. The two Geref sermorelin approvals were withdrawn effective June 18, 2009, after the maker EMD Serono asked for withdrawal, and FDA later determined that the Geref products were not withdrawn from sale for reasons of safety or effectiveness.3 FDA's briefing says ipamorelin is not a component of an FDA-approved drug.2
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- RxList. Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings. rxlist.com
- US FDA. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- Federal Register / FDA. Federal Register, Volume 78 Issue 42 (Monday, March 4, 2013). govinfo.gov
- PubMed. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. 1996. pubmed.ncbi.nlm.nih.gov
- PubMed. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. 1997. pubmed.ncbi.nlm.nih.gov
- PubMed. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. 2014. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01280344: Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. 2014. clinicaltrials.gov
- ClinicalTrials.gov. NCT00672074: Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. 2009. clinicaltrials.gov
- HPRA (Ireland) summary of product characteristics. License. assets.hpra.ie
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted